Capricorn Fund Managers Ltd Invests $1.76 Million in Boston Scientific Corporation $BSX

Capricorn Fund Managers Ltd acquired a new stake in Boston Scientific Corporation (NYSE:BSX) during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund acquired 28,100 shares of the medical equipment provider’s stock, valued at approximately $1,763,000.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the business. Claret Asset Management Corp raised its holdings in Boston Scientific by 4.4% in the third quarter. Claret Asset Management Corp now owns 2,400 shares of the medical equipment provider’s stock valued at $234,000 after buying an additional 102 shares during the period. Outfitters Financial LLC grew its stake in Boston Scientific by 0.5% during the fourth quarter. Outfitters Financial LLC now owns 24,027 shares of the medical equipment provider’s stock worth $2,291,000 after buying an additional 110 shares during the period. Fayez Sarofim & Co increased its position in shares of Boston Scientific by 2.1% in the third quarter. Fayez Sarofim & Co now owns 5,327 shares of the medical equipment provider’s stock worth $520,000 after acquiring an additional 111 shares in the last quarter. Natural Investments LLC increased its position in shares of Boston Scientific by 2.9% in the fourth quarter. Natural Investments LLC now owns 4,036 shares of the medical equipment provider’s stock worth $384,000 after acquiring an additional 112 shares in the last quarter. Finally, Old Port Advisors raised its stake in shares of Boston Scientific by 4.7% in the 4th quarter. Old Port Advisors now owns 2,558 shares of the medical equipment provider’s stock valued at $244,000 after acquiring an additional 115 shares during the period. Institutional investors and hedge funds own 89.07% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts recently weighed in on BSX shares. The Goldman Sachs Group set a $71.00 target price on shares of Boston Scientific in a report on Thursday, May 28th. Wells Fargo & Company reiterated an “equal weight” rating and issued a $55.00 price target (down from $75.00) on shares of Boston Scientific in a report on Thursday, May 28th. Leerink Partners cut their price objective on Boston Scientific from $87.00 to $74.00 and set an “outperform” rating on the stock in a research report on Thursday, May 28th. Jefferies Financial Group reduced their price objective on Boston Scientific from $100.00 to $67.00 and set a “buy” rating on the stock in a research note on Wednesday, June 24th. Finally, Raymond James Financial reaffirmed an “outperform” rating and issued a $88.00 target price (down from $97.00) on shares of Boston Scientific in a research report on Monday, March 30th. One analyst has rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating, five have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Boston Scientific presently has a consensus rating of “Moderate Buy” and a consensus target price of $83.36.

Boston Scientific Price Performance

Shares of BSX stock opened at $42.64 on Wednesday. The firm has a fifty day simple moving average of $52.04 and a 200-day simple moving average of $70.28. The company has a market capitalization of $63.38 billion, a PE ratio of 17.84, a price-to-earnings-growth ratio of 0.83 and a beta of 0.56. Boston Scientific Corporation has a twelve month low of $42.25 and a twelve month high of $109.50. The company has a current ratio of 1.90, a quick ratio of 1.22 and a debt-to-equity ratio of 0.42.

Boston Scientific (NYSE:BSX) last released its quarterly earnings results on Wednesday, April 22nd. The medical equipment provider reported $0.80 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.79 by $0.01. Boston Scientific had a net margin of 17.29% and a return on equity of 19.17%. The firm had revenue of $5.20 billion for the quarter, compared to the consensus estimate of $5.19 billion. During the same quarter in the previous year, the firm posted $0.75 EPS. The firm’s quarterly revenue was up 11.6% on a year-over-year basis. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. Equities research analysts anticipate that Boston Scientific Corporation will post 3.36 earnings per share for the current fiscal year.

Boston Scientific declared that its board has approved a share buyback plan on Monday, May 18th that authorizes the company to buyback $5.00 billion in outstanding shares. This buyback authorization authorizes the medical equipment provider to purchase up to 6.4% of its stock through open market purchases. Stock buyback plans are often a sign that the company’s board of directors believes its stock is undervalued.

Insider Transactions at Boston Scientific

In other Boston Scientific news, Director Cheryl Pegus acquired 1,770 shares of the stock in a transaction on Wednesday, May 20th. The stock was purchased at an average price of $56.49 per share, for a total transaction of $99,987.30. Following the purchase, the director directly owned 1,770 shares in the company, valued at $99,987.30. This trade represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Edward J. Ludwig acquired 3,580 shares of the company’s stock in a transaction on Wednesday, May 20th. The shares were acquired at an average price of $56.68 per share, for a total transaction of $202,914.40. Following the completion of the acquisition, the director directly owned 25,359 shares in the company, valued at $1,437,348.12. The trade was a 16.44% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Over the last ninety days, insiders have acquired 9,800 shares of company stock valued at $554,012. 0.34% of the stock is currently owned by insiders.

Trending Headlines about Boston Scientific

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Boston Scientific completed its POLARx Post Approval Study, adding fresh clinical data to its atrial fibrillation growth narrative and supporting confidence in its cardiac ablation pipeline. Boston Scientific’s POLARx Study Completion Adds Fresh Data to Atrial Fibrillation Growth Story
• Positive Sentiment: The company’s recent revenue trend remains strong, with Q1 2026 sales of $5.2 billion, up 11.6% year over year, and Wall Street analysts still showing a generally constructive long-term view despite recent stock weakness.
• Neutral Sentiment: Boston Scientific’s $1.5 billion investment in MiRus, along with an option to acquire its TAVR system, signals continued strategic expansion in structural heart and implant technologies. Boston Scientific (BSX) Invests $1.5B in MiRus for Equity Stake and TAVR Acquisition Option
• Neutral Sentiment: Erste Group trimmed near-term earnings estimates slightly, but the revisions were modest and still aligned with consensus for FY2026, suggesting limited new fundamental change. Boston Scientific analyst estimate update
• Negative Sentiment: Recent analyst downgrades and lower price targets have weighed on sentiment, with concerns centered on softer Watchman demand, procedure bundling, and broader medtech industry pressure. Boston Scientific Stock (BSX) Opinions on Recent Analyst Downgrades
• Negative Sentiment: The stock’s weak technical setup and proximity to multi-year lows are also contributing to selling pressure, as investors remain cautious about the timing of any recovery.

Boston Scientific Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.